Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Akorn, Inc. (AKRX - Snapshot Report) and Hi-Tech Pharmacal Co., Inc. recently entered into an agreement according to which Hi-Tech will be acquired by Akorn for $43.50 per share or $640 million in cash.

The offer price reflects a 23.5% premium on the closing price on the day before the acquisition was announced.

Hi-Tech focuses on specialty manufacturing and marketing of prescription, over-the-counter and nutritional products.

Hi-Tech’s specialty lies in manufacturing liquid and semi-solid dosage forms. It also produces and markets a range of oral solutions and suspensions, as well as topical ointments and creams, nasal sprays, otics, sterile ophthalmics and sterile ointment and gels products.  

Akorn expects the acquisition to provide annual run-rate synergies of $15-$20 million within 12 months after the acquisition is completed. Post acquisition, annual revenues are expected to exceed $500 million. It is expected that the deal will be accretive to Akorn’s non-GAAP adjusted earnings per share immediately upon completion. Akorn expects the transaction to close in the first quarter of 2014.

The acquisition will broaden Akorn’s product portfolio and substantially increase its retail presence in prescription as well as OTC products.

Akorn, which is currently the third largest U.S. generic ophthalmic player, will experience pipeline expansion through this acquisition. Post acquisition, the combined unit will have 73 abbreviated new drug applications (ANDAs) filed with the U.S. Food and Drug Administration (FDA) of which 57 belongs to Akorn and 18 will come from Hi-Tech.

Akorn currently carries a Zacks Rank #2 (Buy), while Hi-Tech carries a Zacks Rank #5 (Strong Sell). A stock that is worth considering is Gilead Sciences Inc. (GILD - Analyst Report) with a Zacks Rank #1 (Strong Buy).

Another acquisition agreement announced recently is that of Sangamo Biosciences Inc. (SGMO - Snapshot Report) and privately-held biotech company Ceregene, Inc.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%